{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:05:47Z","timestamp":1784401547066,"version":"3.55.0"},"reference-count":80,"publisher":"Edizioni Minerva Medica","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Angiol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.23736\/s0392-9590.23.05110-6","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T06:40:52Z","timestamp":1697092852000},"source":"Crossref","is-referenced-by-count":11,"title":["Lower extremity arterial disease perspective: IUA consensus document on \"lead management\". Part 1"],"prefix":"10.23736","volume":"42","author":[{"given":"Pier Luigi","family":"ANTIGNANI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"GARGIULO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"GASTALDI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"JAWIEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"MANSILHA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"POREDOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17149","reference":[{"key":"10.23736\/S0392-9590.23.05110-6_ref001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref002","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.3390\/ijms160714477","article-title":"Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?","volume":"16","author":"Poredo\u0161 P","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.23736\/S0392-9590.23.05110-6_ref003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1358863X13503695","article-title":"n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial","volume":"18","author":"Grenon SM","year":"2013","journal-title":"Vasc Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref004","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes FG","year":"2013","journal-title":"Lancet"},{"key":"10.23736\/S0392-9590.23.05110-6_ref005","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association","volume":"144","author":"Criqui MH","year":"2021","journal-title":"Circulation"},{"key":"10.23736\/S0392-9590.23.05110-6_ref006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-016-0446-x","article-title":"Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study","volume":"15","author":"Mohammedi K","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref007","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2337\/diacare.29.03.06.dc05-1567","article-title":"Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study","volume":"29","author":"Norman PE","year":"2006","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref008","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/diacare.25.5.894","article-title":"UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes","volume":"25","author":"Adler AI","year":"2002","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref009","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","article-title":"Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome","volume":"24","author":"Jude EB","year":"2001","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.avsg.2016.12.015","article-title":"A Meta-analysis of Long-term Mortality and Associated Risk Factors following Lower Extremity Amputation","volume":"42","author":"Stern JR","year":"2017","journal-title":"Ann Vasc Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref011","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/ATVBAHA.119.312304","article-title":"Perivascular Adipocytes in Vascular Disease","volume":"39","author":"Kim HW","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref012","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.jfas.2016.01.012","article-title":"Mortality After Nontraumatic Major Amputation Among Patients With\u00a0Diabetes and Peripheral Vascular Disease: A Systematic Review","volume":"55","author":"Thorud JC","year":"2016","journal-title":"J Foot Ankle Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1024\/0301-1526\/a000835","article-title":"Conservative treatment for PAD - Risk factor management","volume":"48","author":"Frank U","year":"2019","journal-title":"Vasa"},{"key":"10.23736\/S0392-9590.23.05110-6_ref014","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher J","year":"2015","journal-title":"Lancet"},{"key":"10.23736\/S0392-9590.23.05110-6_ref015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine MS","year":"2017","journal-title":"N Engl J Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref016","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1024\/0301-1526\/a000969","article-title":"Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease","volume":"50","author":"Belch JJ","year":"2021","journal-title":"Vasa"},{"key":"10.23736\/S0392-9590.23.05110-6_ref017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.jhh.1001209","article-title":"Peripheral vascular disease and hypertension: a forgotten association?","volume":"15","author":"Makin A","year":"2001","journal-title":"J Hum Hypertens"},{"key":"10.23736\/S0392-9590.23.05110-6_ref018","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/archinte.1991.00400090063012","article-title":"Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials","volume":"151","author":"Radack K","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"\u00d6stergren J","year":"2004","journal-title":"Eur Heart J"},{"key":"10.23736\/S0392-9590.23.05110-6_ref020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000477572","article-title":"Plasma ET-1 Concentrations are Elevated in Patients with Hypertension - Meta-Analysis of Clinical Studies","volume":"42","author":"Xu M","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.23736\/S0392-9590.23.05110-6_ref021","first-page":"14","article-title":"Treadmill exercise-induced release of endothelin-1 in patients with peripheral arterial occlusive disease at Fontaine stage IIb","volume":"19","author":"Mangiafico RA","year":"2000","journal-title":"Int Angiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref022","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede P","year":"2008","journal-title":"N Engl J Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists' Collaboration","year":"2002","journal-title":"BMJ"},{"key":"10.23736\/S0392-9590.23.05110-6_ref024","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger JS","year":"2009","journal-title":"JAMA"},{"key":"10.23736\/S0392-9590.23.05110-6_ref025","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"Fowkes FG","year":"2010","journal-title":"JAMA"},{"key":"10.23736\/S0392-9590.23.05110-6_ref026","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid KR","year":"2006","journal-title":"Am J Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref027","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt DL","year":"2006","journal-title":"N Engl J Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrcardio.2016.24","article-title":"Vascular disease: vorapaxar for the treatment of PAD","volume":"13","author":"Huynh K","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref029","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom JW","year":"2017","journal-title":"N Engl J Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref030","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.2337\/dc22-S004","article-title":"American Diabetes Association Professional Practice, Committee, Committee American Diabetes Association Professional Practice. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022","volume":"45","author":"Draznin B","year":"2022","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref031","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee S","year":"2017","journal-title":"Lancet"},{"key":"10.23736\/S0392-9590.23.05110-6_ref032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath MY","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref033","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.vph.2011.03.007","article-title":"Cellular and molecular mechanisms of vascular injury in diabetes-part II: cellular mechanisms and therapeutic targets","volume":"54","author":"Madonna R","year":"2011","journal-title":"Vascul Pharmacol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref034","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1475-2840-11-37","article-title":"Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise","volume":"11","author":"Keats EC","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref035","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7150\/ijbs.7502","article-title":"The vascular endothelium and human diseases","volume":"9","author":"Rajendran P","year":"2013","journal-title":"Int J Biol Sci"},{"key":"10.23736\/S0392-9590.23.05110-6_ref036","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1210\/jc.2016-2030","article-title":"Endothelial Dysfunction as a Link Between Cardiovascular Risk Factors and Peripheral Neuropathy in Diabetes","volume":"101","author":"Roustit M","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.23736\/S0392-9590.23.05110-6_ref037","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ajcn\/75.4.767","article-title":"Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells","volume":"75","author":"Mohanty P","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.23736\/S0392-9590.23.05110-6_ref038","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.2337\/dc09-S330","article-title":"Endothelial dysfunction as a target for prevention of cardiovascular disease","volume":"32","author":"Versari D","year":"2009","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref039","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/jcb.26097","article-title":"Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked?","volume":"118","author":"Rehman K","year":"2017","journal-title":"J Cell Biochem"},{"key":"10.23736\/S0392-9590.23.05110-6_ref040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12916-017-0901-x","article-title":"Environmental\/lifestyle factors in the pathogenesis and prevention of type 2 diabetes","volume":"15","author":"Kolb H","year":"2017","journal-title":"BMC Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref041","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc18-0695","article-title":"Prognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 Diabetes","volume":"41","author":"Nativel M","year":"2018","journal-title":"Diabetes Care"},{"key":"10.23736\/S0392-9590.23.05110-6_ref042","doi-asserted-by":"crossref","first-page":"e3266","DOI":"10.1002\/dmrr.3266","article-title":"Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update)","volume":"36","author":"Schaper NC","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.23736\/S0392-9590.23.05110-6_ref043","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd22-as01","article-title":"Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers","volume":"40","author":"American Diabetes Association","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.23736\/S0392-9590.23.05110-6_ref044","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/ehjqcco\/qcz037","article-title":"Cardiovascular long-term outcome and prophylactic treatment patterns in peripheral arterial disease in a population-based cohort","volume":"5","author":"Sartipy F","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.23736\/S0392-9590.23.05110-6_ref045","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans V","year":"2018","journal-title":"Eur Heart J"},{"key":"10.23736\/S0392-9590.23.05110-6_ref046","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5603\/AA.2019.0015","article-title":"Recommendations for the management of lower extremity artery disease (LEAD) based on ESVS\/ESC 2017 guidelines. Position document of PTChN, PTNT, PTLR and SFSN PTK experts","volume":"25","author":"Jawien A","year":"2019","journal-title":"Acta Angiologica"},{"key":"10.23736\/S0392-9590.23.05110-6_ref047","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/ejvs.2002.1948","article-title":"Management of secondary risk factors in patients with intermittent claudication","volume":"26","author":"Cassar K","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref048","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11606-006-5042-4","article-title":"Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease","volume":"12","author":"McDermott MM","year":"1997","journal-title":"J Gen Intern Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref049","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1001\/archinte.160.19.2934","article-title":"Determinants of peripheral arterial disease in the elderly: the Rotterdam study","volume":"160","author":"Meijer WT","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.23736\/S0392-9590.23.05110-6_ref050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/oxfordjournals.aje.a116294","article-title":"Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study","volume":"135","author":"Fowkes FG","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref051","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1532-5415.1985.tb02853.x","article-title":"Update on some epidemiologic features of intermittent claudication: the Framingham Study","volume":"33","author":"Kannel WB","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"10.23736\/S0392-9590.23.05110-6_ref052","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oxfordjournals.aje.a010293","article-title":"Prospective study of diet, lifestyle, and intermittent claudication in male smokers","volume":"151","author":"T\u00f6rnwall ME","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref053","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC Guideline on the management of patients with lower peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman MD","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref054","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/jech.47.6.475","article-title":"Physical activity and risk of peripheral arterial disease in the general population: Edinburgh Artery Study","volume":"47","author":"Housley E","year":"1993","journal-title":"J Epidemiol Community Health"},{"key":"10.23736\/S0392-9590.23.05110-6_ref055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmj.328.7441.711-b","article-title":"Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH)","volume":"328","author":"Piepoli MF","year":"2004","journal-title":"BMJ"},{"key":"10.23736\/S0392-9590.23.05110-6_ref056","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1532-5415.2002.50604.x","article-title":"Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials","volume":"50","author":"Regensteiner JG","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.23736\/S0392-9590.23.05110-6_ref057","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren FL","year":"2021","journal-title":"Eur Heart J"},{"key":"10.23736\/S0392-9590.23.05110-6_ref058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","journal-title":"Eur Heart J"},{"key":"10.23736\/S0392-9590.23.05110-6_ref059","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.23736\/S0392-9590.23.05110-6_ref060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand SS","year":"2018","journal-title":"Lancet"},{"key":"10.23736\/S0392-9590.23.05110-6_ref061","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: the\u00a0COMPASS Trial","volume":"71","author":"Anand SS","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref062","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.14324","article-title":"Sulodexide in venous disease","volume":"17","author":"Carroll BJ","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.23736\/S0392-9590.23.05110-6_ref063","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bcp.2019.04.021","article-title":"Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway","volume":"166","author":"Raffetto JD","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.23736\/S0392-9590.23.05110-6_ref064","first-page":"1","article-title":"Vascular pathologies and inflammation: the anti-inflammatory properties of sulodexide","volume":"19","author":"Mattana P","year":"2012","journal-title":"Ital J Vasc Endovasc Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref065","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2478\/ams-2013-0016","article-title":"Sulodexide modifies intravascular homeostasis what affects function of the endothelium","volume":"58","author":"Po\u0142ubi\u0144ska A","year":"2013","journal-title":"Adv Med Sci"},{"key":"10.23736\/S0392-9590.23.05110-6_ref066","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1159\/000453157","article-title":"Sulodexide reduces the proinflammatory effect of serum from patients with peripheral artery disease in human arterial endothelial cells","volume":"40","author":"Sosi\u0144ska P","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.23736\/S0392-9590.23.05110-6_ref067","doi-asserted-by":"crossref","first-page":"CR222","DOI":"10.12659\/MSM.881719","article-title":"Sulodexide reduces senescence-related changes in human endothelial cells","volume":"17","author":"Suminska-Jasinska K","year":"2011","journal-title":"Med Sci Monit"},{"key":"10.23736\/S0392-9590.23.05110-6_ref068","first-page":"112","article-title":"Sulodexide - mixture of glycosaminoglycans with the protective effect towards the vascular endothelium","volume":"20","author":"Br\u0119borowicz A","year":"2014","journal-title":"Acta Angiologica."},{"key":"10.23736\/S0392-9590.23.05110-6_ref069","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1053\/euhj.2001.3033","article-title":"Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study","volume":"23","author":"Coccheri S","year":"2002","journal-title":"Eur Heart J"},{"key":"10.23736\/S0392-9590.23.05110-6_ref070","article-title":"Sulodexide improves pain-free walking distance in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis","volume":"9","author":"Gaddi AV","year":"2020","journal-title":"JRSM Cardiovasc Dis"},{"key":"10.23736\/S0392-9590.23.05110-6_ref071","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s12325-020-01232-1","article-title":"Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis","volume":"37","author":"Bignamini AA","year":"2020","journal-title":"Adv Ther"},{"key":"10.23736\/S0392-9590.23.05110-6_ref072","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1613116","article-title":"Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers","volume":"87","author":"Coccheri S","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.23736\/S0392-9590.23.05110-6_ref073","first-page":"CD010694","article-title":"Sulodexide for treating venous leg ulcers","volume":"2016","author":"Wu B","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.23736\/S0392-9590.23.05110-6_ref074","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.115.016930","article-title":"Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"132","author":"Andreozzi GM","year":"2015","journal-title":"Circulation"},{"key":"10.23736\/S0392-9590.23.05110-6_ref075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1055\/s-0040-1716874","article-title":"Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials","volume":"46","author":"Bikdeli B","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.23736\/S0392-9590.23.05110-6_ref076","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s12325-021-01620-1","article-title":"Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis","volume":"38","author":"Bignamini AA","year":"2021","journal-title":"Adv Ther"},{"key":"10.23736\/S0392-9590.23.05110-6_ref077","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12938-018-0494-4","article-title":"Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods","volume":"17","author":"Shabani Varaki E","year":"2018","journal-title":"Biomed Eng Online"},{"key":"10.23736\/S0392-9590.23.05110-6_ref078","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte MS","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref079","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jvs.2018.11.034","article-title":"A prognostic score for clinical success after revascularization of critical limb ischemia in hemodialysis patients","volume":"70","author":"Abualhin M","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.23736\/S0392-9590.23.05110-6_ref080","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.105.607390","article-title":"Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"114","author":"Rajagopalan S","year":"2006","journal-title":"Circulation"}],"container-title":["International Angiology"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R34Y2023N05A0382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T13:54:02Z","timestamp":1701093242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R34Y2023N05A0382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":80,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.23736\/s0392-9590.23.05110-6","relation":{},"ISSN":["0392-9590","1827-1839"],"issn-type":[{"value":"0392-9590","type":"print"},{"value":"1827-1839","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}